Poseida raises $142M in Series C round to advance multiple myeloma CAR-T, preclinical cell therapies
The company has initiated a Phase II registration trial of a CAR-T that could compete against bluebird and Janssen. CEO Eric Ostertag noted it will dose the first patient in May or June.